Rakovina Therapeutics Gears Up for Key Partnering Sessions in January
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a groundbreaking biopharmaceutical company committed to advancing unique cancer therapies through AI-powered drug discovery, is set to attend important meetings during the annual J.P. Morgan Healthcare Conference. This significant event will occur in San Francisco, marking a pivotal moment for the company as they engage with potential partners and investors.
Anticipation Builds for JPM Week Gatherings
The week of the J.P. Morgan Healthcare Conference is renowned for bringing together prominent figures from the global biotech and pharmaceutical sectors. Jeffrey Bacha, executive chairman of Rakovina, expressed enthusiasm for the opportunities this event presents. He stated, “JPM week brings together a broad cross-section of global biotech and pharma leaders, and it remains one of the most efficient windows of the year for high-quality, in-person partnering discussions.”
Exploring Strategic Partnerships
During these meetings, Rakovina’s leadership team aims to discuss potential collaborations that can align with their innovative technology and long-term objectives. With the field of AI drug development rapidly expanding, the interest in Rakovina's work is at an all-time high, particularly following the promising data presented at the Society for Neuro-Oncology meeting in late 2025.
Innovative Solutions in Cancer Therapy
Rakovina has recently announced groundbreaking preclinical data highlighting the effectiveness of its AI-designed ATR/mTOR dual inhibitors. These inhibitors are not only capable of effectively penetrating the central nervous system—a significant limitation of current treatments—but also demonstrate potency that matches or even exceeds established clinical comparators. This innovation suggests a strong potential for enhanced treatments, especially for cancers impacting brain function.
Connecting with Interested Partners
Organizations and individuals interested in setting up a meeting with Rakovina during this important week are encouraged to reach out to Michelle Seltenrich, the Company’s Director of Corporate Development. This outreach represents a chance for prospective collaborators to engage with Rakovina’s leading-edge technology and vision for cancer treatment.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is dedicated to revolutionizing cancer treatment through innovative research. The company leverages state-of-the-art technologies aimed at targeting the DNA damage response. By utilizing its proprietary platforms, Deep-Docking™ and Enki™, Rakovina can advance the evaluation and enhancement of drug candidates at unprecedented speeds.
A Vision for Future Therapies
With a robust pipeline of DNA-damage response inhibitors, Rakovina aims to progress one or more drug candidates into human clinical trials in partnership with pharmaceutical companies. This ambitious goal highlights the Company’s commitment to exploring new and effective treatment options for patients.
Frequently Asked Questions
What is the purpose of Rakovina Therapeutics attending JPM Week?
The primary goal is to engage with potential partners and investors to explore collaborative opportunities aligned with their innovative cancer therapies.
What recent advancements has Rakovina made?
Rakovina has released preclinical data showcasing the effectiveness of AI-designed ATR/mTOR dual inhibitors, particularly in addressing brain-involved tumors.
How can interested parties connect with Rakovina Therapeutics during JPM Week?
Interested individuals can contact Michelle Seltenrich via email to schedule a meeting during the conference.
What technologies does Rakovina Therapeutics utilize in its drug discovery process?
The company employs AI-powered platforms, specifically Deep-Docking™ and Enki™, to optimize and accelerate drug candidate development.
What are Rakovina’s long-term objectives?
Rakovina aims to advance its drug candidates into human clinical trials while building strategic partnerships within the pharmaceutical industry.
